2
IRUS Total
Downloads

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

File Description SizeFormat 
BSG vaccine PS journal submission v3.0_clean.docxAccepted version155.07 kBMicrosoft WordView/Open
Appendix 1_vaccine milestones.docxAccepted version32.96 kBMicrosoft WordView/Open
Appendix 2_Top tips.docxAccepted version13.97 kBMicrosoft WordView/Open
Appendix 3_members of BSG IBD committee and CRG.docxAccepted version12.41 kBMicrosoft WordView/Open
Figure 1.pdfAccepted version122.82 kBAdobe PDFView/Open
Figure 2.pdfAccepted version78.16 kBAdobe PDFView/Open
Title: SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
Authors: Alexander, J
Hart, A
Segal, JP
Powell, N
Item Type: Journal Article
Abstract: SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
Issue Date: 1-Mar-2021
Date of Acceptance: 13-Jan-2021
URI: http://hdl.handle.net/10044/1/85567
ISSN: 2468-1253
Publisher: Elsevier
Start Page: 218
End Page: 224
Journal / Book Title: The Lancet Gastroenterology and Hepatology
Volume: 6
Issue: 3
Copyright Statement: © 2021 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Crohn's & Colitis UK
Imperial College Healthcare NHS Trust- BRC Funding
Funder's Grant Number: M2019/2 Powell
RDA27
Keywords: Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
INFLUENZA VACCINE
IMMUNE-RESPONSES
CROHNS-DISEASE
IMMUNOSUPPRESSION
CHILDREN
THERAPY
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
ChAdOx1 nCoV-19
Disease Transmission, Infectious
Gastroenterology
Humans
Immunocompromised Host
Inflammatory Bowel Diseases
SARS-CoV-2
Societies, Medical
United Kingdom
Vaccination
Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group
Humans
Inflammatory Bowel Diseases
Vaccination
Gastroenterology
Immunocompromised Host
Societies, Medical
Disease Transmission, Infectious
United Kingdom
COVID-19
SARS-CoV-2
COVID-19 Vaccines
BNT162 Vaccine
2019-nCoV Vaccine mRNA-1273
ChAdOx1 nCoV-19
Publication Status: Published
Online Publication Date: 2021-01-26
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Faculty of Medicine
Imperial College London COVID-19



This item is licensed under a Creative Commons License Creative Commons